Balyasny Asset Management LLC Nektar Therapeutics Transaction History

Balyasny Asset Management LLC

  • $58 Billion
  • Q3 2024

A detailed history of Balyasny Asset Management LLC transactions in Nektar Therapeutics stock. As of the latest transaction made, Balyasny Asset Management LLC holds 300,352 shares of NKTR stock, worth $273,320. This represents 0.0% of its overall portfolio holdings.

Number of Shares
300,352
Previous 264,063 13.74%
Holding current value
$273,320
Previous $327,000 19.27%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$1.11 - $1.48 $40,280 - $53,707
36,289 Added 13.74%
300,352 $390,000
Q2 2024

Aug 14, 2024
SELL
$0.9 - $1.83 $32,013 - $65,093
-35,570 Reduced 11.87%
264,063 $327,000
Q1 2024

May 13, 2024
SELL
$0.49 - $0.96 $392,179 - $768,352
-800,367 Reduced 72.76%
299,633 $278,000
Q4 2023

Feb 14, 2024
SELL
$0.42 - $0.57 $98,140 - $133,190
-233,668 Reduced 17.52%
1,100,000 $616,000
Q3 2023

Nov 14, 2023
BUY
$0.51 - $1.05 $657,490 - $1.35 Million
1,289,198 Added 2899.03%
1,333,668 $800,000
Q2 2023

Aug 14, 2023
BUY
$0.53 - $1.03 $23,569 - $45,804
44,470 New
44,470 $25,000
Q3 2022

Nov 14, 2022
BUY
$3.04 - $5.14 $44,116 - $74,591
14,512 New
14,512 $46,000
Q2 2022

Aug 15, 2022
SELL
$3.17 - $6.17 $2.12 Million - $4.13 Million
-668,827 Closed
0 $0
Q1 2022

May 16, 2022
BUY
$4.16 - $13.72 $2.66 Million - $8.76 Million
638,347 Added 2094.31%
668,827 $3.61 Million
Q4 2021

Feb 14, 2022
SELL
$10.83 - $18.41 $1.55 Million - $2.63 Million
-143,038 Reduced 82.43%
30,480 $412,000
Q3 2021

Nov 15, 2021
BUY
$13.07 - $18.84 $2.27 Million - $3.27 Million
173,518 New
173,518 $3.12 Million
Q1 2020

May 15, 2020
SELL
$14.47 - $27.96 $1.94 Million - $3.75 Million
-134,277 Closed
0 $0
Q4 2019

Feb 14, 2020
BUY
$15.87 - $23.12 $2.13 Million - $3.1 Million
134,277 New
134,277 $2.9 Million
Q3 2019

Nov 14, 2019
SELL
$16.91 - $36.27 $2.74 Million - $5.87 Million
-161,829 Closed
0 $0
Q2 2019

Aug 14, 2019
SELL
$31.0 - $36.3 $359,662 - $421,152
-11,602 Reduced 6.69%
161,829 $5.76 Million
Q1 2019

May 15, 2019
BUY
$31.58 - $46.35 $2.33 Million - $3.41 Million
73,637 Added 73.79%
173,431 $5.83 Million
Q4 2018

Feb 14, 2019
BUY
$30.43 - $56.65 $2.63 Million - $4.89 Million
86,293 Added 639.16%
99,794 $3.28 Million
Q3 2018

Nov 14, 2018
SELL
$46.46 - $68.49 $720,083 - $1.06 Million
-15,499 Reduced 53.44%
13,501 $823,000
Q4 2017

Feb 14, 2018
SELL
$23.02 - $60.5 $17.6 Million - $46.2 Million
-763,782 Reduced 96.34%
29,000 $1.73 Million
Q3 2017

Nov 14, 2017
BUY
$17.79 - $24.0 $14.1 Million - $19 Million
792,782
792,782 $19 Million

Others Institutions Holding NKTR

# of Institutions
145
Shares Held
139M
Call Options Held
32.6K
Put Options Held
14.1K
View Full List

About NEKTAR THERAPEUTICS

NKTR Quotes by TradingView
  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $171M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Balyasny Asset Management LLC Portfolio

Follow Balyasny Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balyasny Asset Management LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email